- Home
- XTKG vs NNVC Comparison
XTKG vs NNVC Comparison
Compare XTKG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- NNVC
- Stock Information
- Founded
- XTKG 1997
- NNVC 2005
- Country
- XTKG Singapore
- NNVC United States
- Employees
- XTKG 178
- NNVC N/A
- Industry
- XTKG
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- NNVC Health Care
- Exchange
- XTKG NYSE
- NNVC Nasdaq
- Market Cap
- XTKG 13.7M
- NNVC 22.0M
- IPO Year
- XTKG 2019
- NNVC N/A
- Fundamental
- Price
- XTKG $0.99
- NNVC $1.19
- Analyst Decision
- XTKG
- NNVC Strong Buy
- Analyst Count
- XTKG 0
- NNVC 1
- Target Price
- XTKG N/A
- NNVC $6.50
- AVG Volume (30 Days)
- XTKG 205.7K
- NNVC 622.6K
- Earning Date
- XTKG 11-27-2024
- NNVC 02-12-2025
- Dividend Yield
- XTKG N/A
- NNVC N/A
- EPS Growth
- XTKG N/A
- NNVC N/A
- EPS
- XTKG N/A
- NNVC N/A
- Revenue
- XTKG $15,234,138.00
- NNVC N/A
- Revenue This Year
- XTKG N/A
- NNVC N/A
- Revenue Next Year
- XTKG N/A
- NNVC N/A
- P/E Ratio
- XTKG N/A
- NNVC N/A
- Revenue Growth
- XTKG 51.59
- NNVC N/A
- 52 Week Low
- XTKG $0.08
- NNVC $1.01
- 52 Week High
- XTKG $2.14
- NNVC $3.59
- Technical
- Relative Strength Index (RSI)
- XTKG 49.71
- NNVC 33.37
- Support Level
- XTKG $0.90
- NNVC $1.42
- Resistance Level
- XTKG $1.38
- NNVC $1.65
- Average True Range (ATR)
- XTKG 0.17
- NNVC 0.11
- MACD
- XTKG -0.02
- NNVC -0.04
- Stochastic Oscillator
- XTKG 23.92
- NNVC 13.21
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.